Abstract
Notch signaling regulates normal squamous cell proliferation and differentiation and is frequently disrupted in squamous cell carcinomas (SCC), where it acts as a key tumor suppressive pathway. To identify the direct targets of Notch that produce these phenotypes, we introduced a conditional Notch transgene into SCC cell lines, which respond to Notch activation by undergoing differentiation. RNA-seq and ChIP-seq analyses show that in squamous cells, Notch activates a context-specific program of gene expression that depends on lineage-specific regulatory elements, most of which lie in long-range enhancers. Among the direct Notch target genes are multiple DNA damage response genes, including IER5, which is regulated by Notch through several enhancer elements. We show that IER5 is required for Notch-induced differentiation in squamous carcinoma cells and in TERT-immortalized keratinocytes. Its function is epistatic to PPP2R2A, which encodes the B55α subunit of PP2A, and IER5 interacts with B55α in cells and in purified systems. These results show that Notch and DNA-damage response pathways converge in squamous cells and that some components of these pathways promote differentiation, which may serve to eliminate DNA-damaged cells from the proliferative pool in squamous epithelia.
Introduction
In the landscape of oncology, the Notch signaling pathway is famously pleiotropic. While it acts as a potent oncogene in T-cell acute lymphoblastic leukemia, it serves as a critical tumor suppressor in squamous cell carcinomas (SCC) of the skin, head, and neck. When Notch signaling is compromised in these tissues, cells fail to exit the cell cycle and remain in a progenitor-like state, leading to uncontrolled proliferation. Conversely, activating Notch in SCC cells triggers a robust program of growth arrest and terminal differentiation.
Despite the clear importance of Notch in squamous biology, the specific molecular "instruction manual" it uses to enforce differentiation has remained elusive. Identifying the direct genetic targets and the biochemical machinery executing these commands is essential for understanding SCC pathogenesis and developing "differentiation therapies" that could force malignant cells to mature and stop dividing.
Mapping the Notch Landscape in Squamous Cells
To identify the immediate effectors of Notch, researchers utilized a "Notch-on" model in SCC cell lines (IC8 and SCCT2) and immortalized keratinocytes. By employing a γ-secretase inhibitor (GSI) washout system, they were able to synchronize the activation of Notch signaling and capture the earliest transcriptional changes.
Integrated genomic analysis using ChIP-seq and RNA-seq revealed that Notch does not have a universal target list. Instead, its activity is highly context-specific. In squamous cells, the Notch transcription complex (NTC) binds to lineage-specific enhancers that are heavily enriched for AP1 motifs. This explains why Notch drives different biological outcomes in the skin compared to the blood; the chromatin landscape of the squamous lineage pre-determines which genes Notch can access.
IER5: A Bridge Between Stress Response and Maturation
One of the most striking findings was the identification of IER5 (Immediate Early Response 5) as a direct and essential Notch target. Traditionally associated with the DNA damage response and cellular stress, IER5 was found to be regulated by Notch through several long-range enhancer elements (specifically enhancers D and E).
Functional studies using CRISPR/Cas9-mediated knockouts demonstrated that IER5 is not merely a marker of Notch activity but a requirement for its function. Cells lacking IER5 failed to upregulate late-stage differentiation markers, such as Keratin 1 (KRT1) and Involucrin (IVL), even when Notch was fully activated. This suggests that Notch hijacks components of the DNA damage response pathway to ensure that cells exit the proliferative pool and undergo maturation.
The IER5-PP2A Signaling Axis
How does a stress-response protein like IER5 drive a complex process like squamous differentiation? Using Tandem Affinity Purification and Mass Spectrometry (TAP-MS), the researchers discovered that IER5 interacts directly with the B55α subunit of Protein Phosphatase 2A (PP2A), encoded by the gene PPP2R2A.
Biochemical assays, including Microscale Thermophoresis, confirmed a high-affinity interaction ($K_d ≈ 100nM$) between IER5 and B55α. In this context, IER5 acts as an inhibitor of the PP2A-B55α complex. The study established a clear epistatic relationship: knocking out PPP2R2A rescued the differentiation defects in IER5-null cells. This proves that the primary role of IER5 in the Notch pathway is to suppress specific PP2A activity, thereby allowing the phosphorylation of downstream substrates necessary for differentiation to persist.
Discussion and Clinical Implications
This research provides a roadmap for understanding how Notch induces the differentiation of squamous cells through context-specific crosstalk with DNA damage response genes and the PP2A phosphatase. While IER5 is a critical piece of the puzzle, it likely works in concert with other Notch-activated factors to execute the full differentiation program.
A major remaining question is the identity of the specific PP2A-B55α substrates. Identifying the proteins that B55α dephosphorylates to maintain the progenitor state will be a vital next step in fully mapping this pathway.
From a therapeutic perspective, these findings are highly encouraging. Because many SCCs retain the downstream machinery of the Notch pathway even after losing the receptor itself, targeting the IER5-PP2A axis—perhaps through PP2A inhibitors—could provide a way to bypass Notch loss and reactivate the differentiation program in cancer cells. This "differentiation therapy" represents a promising strategy for treating aggressive squamous cell carcinomas.
Summary updated